



LKT Laboratories, Inc.

OTX-015

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID O7992

CAS No. 202590-98-5

Chemical Name

Synonym OTX015; Y-803; Birabresib; MK-8626; MK8628

Formula $C_{25}H_{22}ClN_5O_2S$

Formula Wt. 491.99

Melting Point


Purity $\geq 98\%$

Solubility DMSO: ≥ 49 mg/mL

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description OTX-015 (Birabresib) is an inhibitor of bromodomains (BRD) proteins such as BRD2/3/4; it is currently in clinical trials as a potential treatment for leukemias and other cancers. OTX-015 displays anticancer chemotherapeutic activity, inhibiting cell growth and tumor growth in various animal models, including anaplastic large cell lymphoma. This compound also induces apoptosis in activated B-cell-like diffuse large B-cell lymphoma cells.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
O7992	1 mg	\$92.70
O7992	5 mg	\$185.40
O7992	10 mg	\$309.00

References Boi M, Gaudio E, Bonetti P, et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clin Cancer Res. 2015 Apr 1;21(7):1628-38.PMID: 25633213.

Noel JK, Iwata K, Ooike S, et al. Development of the BET bromodomains inhibitor OTX015. Mol Cancer Ther. 2013 Nov;12:C244.

Boi M, Todaro M, Vurchio V, et al. OTX015, a bromodomains and extraterminal inhibitor, represents a novel agent for ALK positive anaplastic large cell lymphoma. Mol Cancer Ther. 2013 Nov;12:A219.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.